chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pt requested FLUBLOK for egg allergy described as GI upset, nausea and loose stools, no resp issues, no hives no other symptoms with eggs. FLUBLOK vaccine given. Apprx 5 min post vaccination was sitting in chair and C/O feeling dizzy and light headed. Had pt lay down on adjacent floor mat. Called in coworker RN BSN. Pt remained awake, no loss of consciousness, skin warm and dry, color Pink. Nurse remained with patient while I went across hall for my supervisor, MPH RN to further evaluate pt. Upon entering clinic room with pt and nurse, Pt was lying on mat with an ice pack to forehead, speaking clearly and sucking on a lollipop. Supervisor present. Pt pulse 72 and strong, BP 106/70, color pink, skin warm and dry. Supervisor and Nurse then left the room. After approximately 15 min pt requested to sit up and said she felt better. Sat up on mat w/o any difficulty. Given a cup of water which was held w/ (R) hand-drank cup of water w/o difficulty. Continued to talk and remained alert and oriented. Took a short walk to chair just outside clinic room w/steady gait. Requested she remain seated for further observation. Given another cup of water (pt request) and a lollipop. Observed drinking water, sucking on lollipop and texting on phone. After apprx 45 min pt said her (R) arm was tingling and felt numb - was holding cup w/(R) hand and demonstrated full ROM (R) arm - Asked her to stand up and try to walk - she stood up quickly and said she felt a little dizzy had her sit back in chair. She then said her (R) leg felt a little numb. Asker her if she had anyone to pick her up and take home. She said no but only lived 1 mile away. Relayed all of the above (numbness, standing up quickly and feeling dizzy and non one to drive her home) to my Supervisor. Requested for supervisor to evaluate pt. Supervisor went over to evaluate and talk to pt - I was not present. Supervisor told pt that when she felt up to it she was free to leave. When I returned pt was gone. Pt was at clinic under observation for at least 1 hour. On 10-29-18 supervisor left a voice message on pt phone (phone had a message w/her name) w/an inquiry of how she was doing. Pt did not return call.
Itchy face , numbness in arm , headache and swollen glands for 5 weeks, chest pains
Reporter discovered client lying on  floor in lobby calling for help approximately 49 minuets after receiving Moderna vaccine.  Client reports left chest pain, which does not radiate. B/P 110/62 PO2 97%, HR 51.  No H/O heart disease. Skin warm and dry to touch. 911 activated. Client monitored while awaiting arrival of paramedics. Client stated after receiving vaccine she became "dizzy and her legs felt cold". Unknown if this information was reported to the nurse in observation.  Client transported to hospital by EMS.
SEVERE PAIN AFTER 2ND INJECT OF ENGERIX-B.  PTS/EMPLOYEES COMPLAINING OF SEVERE PAIN AFTER INJECTION (DELTOID) OF 2ND DOSE OF ENGERIX-B.
Gums started to bleed, eyes very bloodshot and watery, very dry mouth all night, diarrhea in the morning.
Briefly, this is a 78-year-old male with a history of CAD, atrial fibrillation,  congestive heart failure, recent mesenteric artery rupture status post abdominal  surgery, who presents to the emergency department for evaluation of generalized  weakness and fatigue.  The patient notes that at home he had been taking his vital signs  and noted tachycardia and hypotension.  On arrival, patient is noted to be tachycardic with heart rate in the 130s and  hypotensive.    At this time, patient continues to receive IV fluids.  Screening work-up has  been performed which shows evidence of acute renal insufficiency and likely  dehydration.  Orthostatic vital signs were performed and are negative but were  performed after a first liter of IV fluids were administered and may be falsely  negative.  Patient is currently on his second liter of IV fluids and continues  to have tachycardia in the 120s.  Given evidence of dehydration and AKI in the  setting of persistent tachycardia despite 2 L of IV fluids I do believe the  patient requires admission to the hospital for continued IV fluid resuscitation  and management of generalized fatigue.  The patient is in agreement with plan  and admitted in stable condition.  Upon admittance to the medical floor, a rapid response was called for sustained SVT heart rate at 200 beats per minute.
Patient is a 32yo G3 now P2102 with EDC 7/20/2021 who was admitted with vaginal bleeding at 31w1d on 5/21/2021. She had an emergent C-section for presumed abruption with EBL 3700ml and subsequent diagnosis of DIC requiring mass-transfusion and ICU admission. Patient stabilized following transfusion, ultimately discharged from hospital 5/25/2021. Neonate died DOL#2 from prematurity/RDS/Anemia/suspected sepsis/metabolic acidosis/cardiopulmonary arrest..
Patient reports: 9/29/08, sore throat, later on a a non productive cough. started on TUSSIN DM, CEPACOL Lozenges which seem to help.
Site: Redness at Injection Site-Mild, Site: Swelling at Injection Site-Mild, Systemic: Lymph Node Swelling-Mild
EMPLOYEE STATES BECAME ILL, STUFFY NOSE, WATERY EYE, STAYED HOME, RESP TREATMENT NECESSARY, GIVEN BENADRYL AT MD OFFICE.
Patient presented to the pharmacy with a COVID Vaccination card stating "3/30/21" on 4/24/21 for their second dose Moderna vaccination (25 days from initial shot). Patient was given the Moderna Vaccine. Upon billing for administration, the insurance informed us that patient received their shot on 4/2/21. When called, the patient confirmed that they missed their appointment on 3/30/21 and received their shot on 4/2/21 but did not inform anyone in the pharmacy. Patient was informed that the grace period for Moderna shot is 4 days early and that this shot was given too early. At this time, their is no recommendation from Agenvy to re-start series or provide another dose. Patient verbalized understanding.
swollen arm; flu like symptoms; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 17-May-2021 and was forwarded to Moderna on 17-May-2021.    This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (swollen arm) and INFLUENZA LIKE ILLNESS (flu like symptoms) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PERIPHERAL SWELLING (swollen arm) and INFLUENZA LIKE ILLNESS (flu like symptoms). At the time of the report, PERIPHERAL SWELLING (swollen arm) and INFLUENZA LIKE ILLNESS (flu like symptoms) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient was scared because of swollen arm and flu.  No Concomitant medicines were reported. No Treatment medicines were reported.   This case was linked to US-MODERNATX, INC.-MOD-2021-138746, US-MODERNATX, INC.-MOD-2021-138764, US-MODERNATX, INC.-MOD-2021-138791 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-138746: US-MODERNATX, INC.-MOD-2021-138764: US-MODERNATX, INC.-MOD-2021-138791:
eyelids are swollen and itchy; eyelids are swollen and itchy; gotten gradually worse the past couple of months; eyelids are swollen and itchy; This is a spontaneous report from a contactable pharmacist. This pharmacist reported for male patient that:  A 51(unit: unknown) male patient received unspecified dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; formulation: Solution for injection, Lot number and Expiry date was not reported) via an unspecified route of administration on an unspecified date as single dose for covid-19 immunisation. The patient medical history was not reported. The patient concomitant medications were not reported. Caller asked about treatment for long term side effects associated with the Pfizer covid 19 vaccine. On unspecified date patient experienced that his side effect has lasted longer than 6 months and has gotten gradually worse the past couple of months. His eye lids are swollen and itchy, noting the eye lids are fully swollen 24 hours a day and very itchy. Caller stated he has tried everything. The outcome of the events was unknown.   Information about lot and batch number was requested.
8-8-13 (R) arm started swelling, hot to touch, after DTAP injection on 8-7-13. 8-9-13 Patient vomited x 2 this AM with fever 102. Mom gave TYLENOL and brought him in. Mother was instructed to apply cool compresses and give TYLENOL mor MOTRIN age appropriate dose. If no better or symptoms worsen, instructed to go to PCP. Child up and active, playful at HD today.
red ring around the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (red ring around the injection site) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Feb-2021, the patient experienced VACCINATION SITE ERYTHEMA (red ring around the injection site). At the time of the report, VACCINATION SITE ERYTHEMA (red ring around the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Concomitant Medications were  provided by Reporter. No Treatment Medications were  provided by Reporter.
Patient was hospitalized due to breakthrough infection. Patient received Pfizer vaccine (2nd dose in series) on 04/22/21. Patient was hospitalized from 11/05/21 - 11/09/21. Below is copied from discharge summary:   Patient 81 y/o F with pmHx of HTN, chronic HFpEF, DM2, chronic Afib on eliquis, recent COVID 19 diagnosis who presents with c/o worsening SOB today, found hypoxic at 87-88% requiring O2 via NC, with elevated pro BNP>3K and evidence of moderate lo large pleural effusions consistent with acute on chronic HFpEF exacerbation. Admitted as inpatient for further management.   Acute hypoxic respiratory failure 2/2 Acute on chronic HFpEF exacerbation with large pleural effusions and atelectasis/ Severe TR, Moderate AR, Moderate MR/pHTN: -Etiology multifactorial, could be increased water/salt intake per Hx and/or cardizem related -O2 98% on oxymizer, will start weaning off as tolerated  -pro BNP>3K -chest Xray: Pleural effusions, atelectasis -CTA chest with moderate to large pleural effusions -TTE from 11/2021 showed: Preserved EF, Severe TR, Moderate AR, Moderate MR,pHTN: - Lasix 40mg given  -xray w bl pleural effusions  -IS and EZPAP -Thoracentesis cancelled due to pt improvement, no o2 need  -switched coreg to metoprolol for HR control, titrated up to 100mg   -s/p digoxin and better  -Cardiology following -walking test for home o2  done and passed, remained >90%    Chronic Afib: -HR uncontrolled today, asymptomatic  -CHADS2VASC of 6 -switched coreg to metoprolol for HR control  -s/p  digoxin w good response -cont eliquis    Hyponatremia: -better -From volume overload in the setting of CHF -Management as above   NSTEMI, demand ischemia: -trop 20, 19 -From above -EKG non ischemic   COVID 19: -Hypoxia due to CHF and less likely due to COVID 19 -crp elevated  -prn meds for symptom managements -Hold off steroids or remdesevir -Contact and droplet isolation   DM2: -Stable -Resume metformin -Accuchecks and SS   HTN: -Controlled -Resume losartan and coreg   HLD: -Resume lipid panel   Obesity, BMI of 21: -would benefit from lifestyles modifications regarding low fat diet, weight loss and daily excercise -F/U OPD with PCP     Patient is discharged in stable condition with stable vital signs. All questions rearding hospital course and plan of care after discharge have been answered to satisfaction. Prescriptions for medications needed to be taken after discharge have been given to patient. Patient has been instructed to follow up with PCP MD within the next 7 days after discharge. Patient verbalizes understanding all given instructions and has no further doubts regarding discharge.
Massive full body pain all joints, all muscles. 101.1 fever last from 10 pm 10/4/21-@12:00AM 10/6/21
About 10 hours after vaccine, patient developed nausea, vomiting, diarrhea, and abdominal pain. She describes these symptoms as severe with multiple, powerful episodes and similar to her Celiac disease when she flares from high gluten meal. She also had low back pain and body aches. The following day symptoms continued. Improved overnight into Jan 10, then worsened after waking up. On Jan 11, no further n/v/d but not feeling back to baseline yet.
Child fine until seizure occurred at 2:00am on 10/6/09. Child had fever of 100 F at time of seizure. Later that afternoon fever rose to 102 degrees and had some congestion (sinus) and dark yellow mucus. 12/7/09 Medical records received for date 10/6/09. DX: febrile seizure. Presenting sx: stomach ache, fever, body shaking then collapsed then vomited. c/o N&V, weakness of limbs. Assessment: WNL.
Arm is throbbing, numb, and tingling to the finger tips, grip is not tight.
This spontaneous report as received from a patient referring to herself a 76 year old female patient. The patient's concurrent conditions included low thyroid, high blood pressure and high cholesterol. She did not present any drug reactions or allergies. The concomitant therapies included unspecified blood pressure pill, cholesterol pill, thyroid medication and antidepressant (unspecified). On an unspecified date "over four years ago", the patient received an injection for the vaccination with ZOSTAVAX (strength, dose, route, frequency, lot # and expiration date were not provided) for prevention of shingles; diluted in 1 shot of sterile diluent (manufacturer unknown) (dose, route, frequency, lot # and expiration date were not provided). Additionally, the patient had "received both doses of SHINGRIX earlier in 2018 (reported as ''this year"). On 20-SEP-2018, the patient had been diagnosed with shingles. She sought medical attention and received treatment for the event (unspecified). The patient also mentioned that she had just had "pelvic prolapse surgery". The patient had not yet recovered from the events. No further adverse event (AE) information provided. The reporter did not provide a causal relationship between the events and the vaccination with ZOSTAVAX vaccine or the sterile diluent (manufacturer unknown). Upon internal review the event of pelvic prolapse was considered to be medically significant as the patient underwent a surgery.
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a male patient of unknown age.  Medical history and concomitant medications were not provided.  On or about 14-JUN-2011, the patient was inoculated with ZOSTAVAX (route and lot # not provided) at a family physician's office as recommended for routine adult health maintenance for the prevention of shingles.  The vaccine did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of herpes zoster.  On or about 30-APR-2016, the patient was treated by a physician for a vesicular oubreak that was diagnosed as herpes zoster "keratis" (shingles in the eye).  He was prescribed valacyclovir (VALTREX) for management of his painful symptoms.  As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages, and required extensive medical care and treatment.  As a further proximate result, he has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages.  Persistent strain of herpes zoster/vesicular oubreak that was diagnosed as herpes zoster "keratis" (shingles in the eye) was considered related to ZOSTAVAX. The outcome of the events was not recovered. Upon internal review, opthalmic herpes zoster was considered medically significant. Additional information has been requested.
Received the injection on the evening of the 4th, woke up the next morning with hives and eczema covering his legs, trunk, back, arms.
Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX vaccine by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 23-JUN-2015, the patient was administered the ZOSTAVAX by a healthcare provider at a hospital (lot number, dosage and route of administration not provided). On or about 06-MAR-2017, the patient was treated by a physician for the following injury resulting from his ZOSTAVAX use: Shingles. The patient claims damages including: injury to himself, loss of consortium, loss of services, and economic losses. The outcome of the shingles is unknown. Additional information has been requested.
mom reports pt has 2 vesicles on 17NOV;by 19NOV rash of >50 lesions progressed to abd, buttocks, back & neck;lesions began to crust on Wed but another crop of lesions started;fever 103.6 1AM;fever reached 101.6;advised treat like chickenpox
Feverish, sweating, mid- level headache, and at 8 pm muscle pain especially in breasts, jaws  and every joint that has arthritis was very painful.  Couldn?t sleep until 3 a.m... Woke up at 5 a.m. and all symptoms were gone. None since.
Patient did not receive 2nd dose of the Moderna vaccine in over 36 days after 1st dose of the Moderna vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Patient did not receive 2nd dose of the Moderna vaccine in over 36 days after 1st dose of the Moderna vaccine) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in January 2021.    In April 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Patient did not receive 2nd dose of the Moderna vaccine in over 36 days after 1st dose of the Moderna vaccine). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Patient did not receive 2nd dose of the Moderna vaccine in over 36 days after 1st dose of the Moderna vaccine) had resolved.            The concomitant medications were not reported. The treatment information was not provided.  Patient reported that she had not received the second dose of Moderna vaccine. She reported that people who had COVID-19 have more antibodies and also she expressed her interest in clinical trial participation.
I began to feel general fatigue, tiredness and congestion. As I was driving my eyes began to burn I got home and my rapid COVID-19 test was negative I had a fever of just under one hundred and one. My doctor scheduled a PCR tests January fifth or sixth 2022 which resulted in a positive. I had an infusion 01/12/2022 and at this point I was almost symptom free. Over the next few months I noticed breathlessness when climbing stairs and being awoke at night with a fast heartbeat. I scheduled an appointment with my doctor 09/19/2022 a dramatic increase in my blood pressure was noticed whereas before it was always on the normal to low side. I was diagnosed with stage 2 hypertension an ECG and heart monitor was ordered. Hypertension has not resolved my Tachycardia somewhat has. A prescription of losartan was ordered but not effective I am now on hydrochlorothiazide which is working.
Headache in both temples 12 hours after vaccination.  Progressive neck, shoulder then hip pain and stiffness over 4 days.  Initially treated with indomethcain 50mg 3x day by doctor with no relief.  Blood work showed elevated SED rate and CRP.  Doctor did an initial prednisone taper.  Symptom relied within 3 hours.  Taper was for 1 week and symptoms returned.  Referred to a Rheumatologist who did further blood work to rule out autoimmune causes.  Platelet count was low along with elevated SED rate and CRP.  Started on 15mg prednisone on 1 June with taper to 12.5 in July and 10 in August then by 1 mg each month.  Working diagnosis is Polymyalgia Rheumatica
Vaccine administered at age of 16; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Vaccine administered at age of 16) in a 16-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 091B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Apr-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Vaccine administered at age of 16). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Vaccine administered at age of 16) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications details were not reported  by the reporter. Treatment details was not reported by the reporter.; Sender's Comments: This report refers to a case of product administered to patient of inappropriate age (16 year old female) for mRNA-1273 (lot number 091B21A) with no associated AEs reported.
Welts developed on back, abd, arms & leg.  Redness & itching. 0 sob Symptoms began 4-21-09 p.m.
Information was received from a lawyer regarding a case in litigation concerning a male patient of unknown age who on 03-APR-2013, was vaccinated with ZOSTAVAX (lot number, dosage, and route of administration not provided) for the prevention of shingles. Prior to receiving the ZOSTAVAX, the patient had never suffered from or been diagnosed with herpes zoster, or any other ailment collectively referred to as "shingles." No other information was provided regarding the patient's past medical history, concurrent conditions, or concomitant medication. On or about 12-NOV-2015, the patient was treated at an urgent care facility for symptoms of constant pain, worsening in severity in his lower extremities. The patient was then diagnosed with herpes zoster, also known as a shingles outbreak. On or about 12-NOV-2015, the patient was prescribed acyclovir for the treatment of shingles and shingles-related nerve pain. As a direct result of ZOSTAVAX, the patient suffered, is suffering and/or will continue to suffer from mental and emotional distress due to resulting physical limitations and seriousness of his condition. As a result of ZOSTAVAX, the patient sustained severe and permanent personal injuries. He suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, a diminished quality of life, physical impairment and injury. Additional information has been requested.
Site injection pain and soreness, swollen, itching and painful area around injection site about 4 inches in diameter.  Starting day of shot lasting now till third day, but today the swelling has gone down.
Progressive headache, leading to ER admission, diagnosis of Left sigmoid sinus thrombosis accompanied by severe thrombocytopenia. Diagnosis confirmed as vaccine-induced immune thrombocytopenia and thrombosis (VITT)/vaccine-associated thrombosis and thrombocytopenia (VATT).